Participant disposition and baseline demographics
Between 18 April 2018 and 6 January 2020, 115 participants were screened, of which 17 participants who met the inclusion criteria were randomized and included in efficacy and safety analyses: placebo, n = 9 (6 male); GSK3772847, n = 8 (6 male). The CONSORT flow diagram is shown in 